Acromegaly
Welcome,         Profile    Billing    Logout  
 23 Companies   9 Products   9 Products   6 Mechanisms of Action   45 Trials   4058 News 


«12...2425262728293031323334...6768»
  • ||||||||||  (OR27) Advances in understanding pathophysiology and management of hypothalamo-pituitary disease (In Person and Livestreamed A313-A314) -  Jul 16, 2022 - Abstract #ENDO2022ENDO_2424;    
    The session will discuss advances in the management of Cushing's, acromegaly and syndrome of inadequate antidiuresis. It will also provide data on the mechanisms implicated in the hyperandrogenemia in Cushing's, the impact of growth hormone nonalcoholic fatty liver disease and malignancies in patients with Prader-Willi syndrome.
  • ||||||||||  Sellar Gangliocytoma-Pituitary Neuroendocrine Tumor (PitNET) Presenting As Acromegaly () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_2148;    
    It may rarely develop in the setting of a growth hormone-secreting PitNET associated with a neuronal tumor composed of neoplastic ganglion cells, the so-called mixed gangliocytoma somatotroph PitNET. We present a case of acromegaly which proved to be due to a mixed gangliocytoma somatotroph PitNET on pathology
  • ||||||||||  Pituitary Adenoma Co-Secreting GH, Prolactin and ACTH () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_2015;    
    This also seemed to impact their confidence in maintaining balance. This is a case report of a patient with clinical features of acromegaly, who was found to have a pituitary tumor that was co-secreting growth hormone, prolactin, and adrenocorticotropic hormone.
  • ||||||||||  Pachydermia lesions identified on imaging in a cohort of acromegaly patients () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_1965;    
    We decided to review the head magnetic resonance imaging of the patients with acromegaly followed at our center and surprisingly found a prevalence of 14%. This study intends to highlight the importance of adequate investigation when this lesions are found on physical examination or in imaging exams, eventually allowing earlier diagnosis and better prognosis for the underlying disease, being acromegaly one of the most important.
  • ||||||||||  Long term follow-up of patient with gigantism harboring an exon 2 deletion in the AIP gene () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_1818;    
    The importance to describe is that even years after the diagnosis the cause of this disease can be evaluated with the new technology. Here we describe a giant patient with deletion of exon 2 of the AIP gene detected by Multiplex Ligation-dependent Probe Amplification assay (MLPA) 33 years after the diagnosis.
  • ||||||||||  IGF-1 and BMI are Associated in Obese Patients with Acromegaly () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_1685;    
    Acromegaly is a disorder of growth hormone (GH) excess, which in turn leads to elevated IGF-1levels. We performed a retrospective study to investigate the relationship between BMI and IGF-1 in patients with clinical acromegaly.
  • ||||||||||  Gynecomastia as the Initial Presentation of Acromegaly. () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_1604;    
    A case of middle-age man who initially presented to our clinic for evaluation of bilateral gynecomastia and hypogonadism. He was found to have growth hormone secreting pituitary macroadenoma with co-secretion of prolactin.
  • ||||||||||  Giant - versus Macroadenomas: Does Size Really Matter in Pituitary Somatotroph Adenomas? () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_1576;    
    To our knowledge, this is the first study that compares the clinical, biochemical, imaging and histopathological features of giant somatotroph pituitary adenomas (n:16) with non-giant macroadenomas (n:57). Our study highlights that giant somatotroph pituitary adenomas require an aggressive multimodal treatment approach and advanced care to achieve sustainable hormonal remission.
  • ||||||||||  Fluctuating Insulin Requirements in Untreated Acromegaly: From 200-to-0 () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_1554;    
    Moreover, no previous cases of acromegaly presenting as DKA has reported glycemic normalization without anti-hyperglycemic therapy prior to any acromegaly treatment. Our case highlights that consideration for acromegaly should be given in patients presenting with severe insulin resistance and pertinent medical history with physical exam features, and emphasizes the dramatic range of insulin requirements in patients with acromegaly.
  • ||||||||||  Familial Carney Complex: Follow Up of a Family With Negative PRKAR1A Genetic Screening () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_1538;    
    This abstract aims to report a rare case of a family with Carney Complex, whose manifestations are Acromegaly, Cardiac Myxomas and testicular tumor. Because of its rarity and because it has a great impact on the quality and life expectancy of patients, we thought it relevant to show the scientific community the presentations found in our case and the absence of mutations in the genetic analysis that could explain the situation.
  • ||||||||||  Evaluation of Elevated IGF-1 in Patients without Clinical Evidence of Acromegaly () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_1511;    
    102 cases without known acromegaly were matched to controls with normal IGF1 levels based upon age, sex, gonadal and pituitary status. The prevalence of dopamine agonist use and chronic kidney disease were both significantly higher in the elevated IGF-1 group compared to the controls.
  • ||||||||||  Diplopia as Presenting Manifestation of Acromegaly () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_1414;    
    This highlights the importance of comprehensive ophthalmic exam in a patient presenting with eye symptoms and features suggestive of acromegaly. Early diagnosis and management of growth hormone excess is of great value in terms of long term morbidity and mortality.
  • ||||||||||  Decreased serum Wnt antagonist levels in patients with active acromegaly () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_1366;    
    Conclusion Patients with active acromegaly exhibited significantly decreased Wnt antagonist levels. The reduction in Wnt antagonists might be involved in the compensatory mechanism of increased bone fragility in active acromegaly.
  • ||||||||||  Cardiovascular Complications in Acromegaly-A National Inpatient Sample Analysis () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_1250;    
    Our study highlights the alarming prevalence of cardiovascular diseases and risk factors for cardiovascular diseases in contemporary acromegaly patients. Therefore, addressing these issues aggressively is very important to improve cardiovascular health and mortality in acromegaly patients.
  • ||||||||||  Chair (In Person and Livestreamed A311-A312) -  Jul 16, 2022 - Abstract #ENDO2022ENDO_719;    
    We did not identify somatic KDM1A mutations in somatotropinomas expressing GIPR ectopically, however their recurrent 1p chromosome loss suggests that KDM1A haploinsufficiency may contribute to GIPR expression in those tumors. This session aims to cover challenging areas in the clinical practice with a special focus on acromegaly and Cushing's disease.Learning Objective 1:To gain insight on the discordant biochemical results in acromegaly and their significance Learning Objective 2:To understand management options and their outcomes in Nelson's syndrome Learning Objective 3:To acquire knowledge on the follow-up and management of patients with Cushing's who had pituitary radiotherapy
  • ||||||||||  Chair (In Person and Livestreamed A311-A312) -  Jul 16, 2022 - Abstract #ENDO2022ENDO_718;    
    This session aims to cover challenging areas in the clinical practice with a special focus on acromegaly and Cushing's disease.Learning Objective 1:To gain insight on the discordant biochemical results in acromegaly and their significance Learning Objective 2:To understand management options and their outcomes in Nelson's syndrome Learning Objective 3:To acquire knowledge on the follow-up and management of patients with Cushing's who had pituitary radiotherapy This session aims to cover challenging areas in the clinical practice with a special focus on acromegaly and Cushing's disease.Learning Objective 1:To gain insight on the discordant biochemical results in acromegaly and their significance Learning Objective 2:To understand management options and their outcomes in Nelson's syndrome Learning Objective 3:To acquire knowledge on the follow-up and management of patients with Cushing's who had pituitary radiotherapy
  • ||||||||||  Journal:  Editorial: Insights Into Acromegaly Complications. (Pubmed Central) -  Jul 15, 2022   
    This session aims to cover challenging areas in the clinical practice with a special focus on acromegaly and Cushing's disease.Learning Objective 1:To gain insight on the discordant biochemical results in acromegaly and their significance Learning Objective 2:To understand management options and their outcomes in Nelson's syndrome Learning Objective 3:To acquire knowledge on the follow-up and management of patients with Cushing's who had pituitary radiotherapy No abstract available
  • ||||||||||  bromocriptine / Generic mfg.
    Review, Journal:  Bromocriptine Therapy: Review of mechanism of action, safety and tolerability. (Pubmed Central) -  Jul 15, 2022   
    Bromocriptine represents an attractive option with high efficacy and safety profile for hyperprolactinemia associated conditions, acromegaly, Parkinsonism, type 2 diabetes mellitus (T2DM) and for various other diseases in a variety of dosage forms for best possible beneficial effects. It appeared to be an effective and safe addition to the pharmacopoeia of drugs for the treatment of vast variety of diseases as monotherapy or in combination with other drugs.
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen
    Enrollment open, Real-world evidence:  Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China (clinicaltrials.gov) -  Jul 14, 2022   
    P=N/A,  N=210, Recruiting, 
    It appeared to be an effective and safe addition to the pharmacopoeia of drugs for the treatment of vast variety of diseases as monotherapy or in combination with other drugs. Not yet recruiting --> Recruiting
  • ||||||||||  Review, Journal:  Acromegaly and Colorectal Neoplasm: An Update. (Pubmed Central) -  Jul 9, 2022   
    All worldwide guidelines and expert consensuses agree with the need for colonoscopic screening and surveillance in acromegaly, although there is no consensus regarding the best period to do this. This review aims to analyze the existing data on CRC and acromegaly, exploring its pathophysiology, epidemiological studies and their limitations, colonic polyp characteristics, overall cancer and CRC incidences and mortality, risk factors for colon cancer pathophysiology, and recommendation guideline aspects.
  • ||||||||||  Journal:  Acromegaly: an endocrine pathology with serious consequences (Pubmed Central) -  Jul 8, 2022   
    After three months of complete transphenoidal surgical resection, biochemical remission was not obtained and the patient was treated by a somatostatin receptor ligand. Based on this severe case with atypical manifestations, the diagnosis of acromegaly should be always considered.
  • ||||||||||  Journal:  From diagnosis to treatment of androgen-secreting ovarian tumors: a practical approach. (Pubmed Central) -  Jul 8, 2022   
    When deriving a differential diagnosis for androgen-secreting ovarian tumors, adrenal gland tumors should be considered as well as typical endocrine pathologies including polycystic ovary syndrome, congenital adrenal hyperplasia, Cushing's disease, and acromegaly. Treatment options for an androgen-secreting ovarian tumors is mainly surgical, but in exceptional cases can involve pharmacotherapy alone.
  • ||||||||||  Journal:  Sex differences in acromegaly. (Pubmed Central) -  Jul 7, 2022   
    Treatment options for an androgen-secreting ovarian tumors is mainly surgical, but in exceptional cases can involve pharmacotherapy alone. No abstract available
  • ||||||||||  Journal:  Gender and age differences among patients with acromegaly. (Pubmed Central) -  Jul 2, 2022   
    According to our results, hypogonadism and greater IGF-1 values are more frequently observed in males. Hyperprolactinemia, hypogonadism and macroadenoma are more frequent in younger patients.
  • ||||||||||  Journal:  Bias in IGF-1 concentrations and interpretation across three different clinical laboratory assays. (Pubmed Central) -  Jul 1, 2022   
    This effect caused nine out of forty-three samples to show falsely elevated results when they were clinically diagnosed as negative for acromegaly. Discussed in the context of previous literature, our findings emphasize the importance of adjusting reference intervals for IGF-1 assays based on the clinical needs of a patient population.